Lori, Adriana http://orcid.org/0000-0001-8686-0148
Schultebraucks, Katharina http://orcid.org/0000-0001-5085-8249
Galatzer-Levy, Isaac
Daskalakis, Nikolaos P. http://orcid.org/0000-0003-1660-9112
Katrinli, Seyma http://orcid.org/0000-0003-1575-8642
Smith, Alicia K. http://orcid.org/0000-0002-8537-5156
Myers, Amanda J.
Richholt, Ryan
Huentelman, Matthew
Guffanti, Guia
Wuchty, Stefan
Gould, Felicia
Harvey, Philip D.
Nemeroff, Charles B.
Jovanovic, Tanja http://orcid.org/0000-0002-6456-0053
Gerasimov, Ekaterina S.
Maples-Keller, Jessica L. http://orcid.org/0000-0003-4768-7332
Stevens, Jennifer S. http://orcid.org/0000-0003-4674-0314
Michopoulos, Vasiliki http://orcid.org/0000-0003-2531-923X
Rothbaum, Barbara O.
Wingo, Aliza P.
Ressler, Kerry J. http://orcid.org/0000-0002-5158-1103
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SCHU/3259/1-1)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (MH106902, MH094759, MH106902)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
Article History
Received: 11 December 2020
Revised: 26 April 2021
Accepted: 24 May 2021
First Online: 29 June 2021
Competing interests
: The data for the analyses described in this manuscript (<i>GRIN3B</i> eQTL variants) were obtained from the GTEx Portal on 12/13/2019. C.B.N discloses the following: Research/Grants: National Institutes of Health (NIH). Consulting (past 12 months): ANeuroTech (division of Anima BV), Signant Health, Sunovion Pharmaceuticals, Inc., Janssen Research and Development LLC, Magstim, Inc., Navitor Pharmaceuticals, Inc., Intra-Cellular Therapies, Inc., EMA Wellness, Acadia Pharmaceuticals, Axsome, Sage, BioXcel Therapeutics, Silo Pharma, XW Pharma, Neuritek, Engrail Therapeutics, and Corcept Therapeutics Pharmaceuticals Company. Stockholder: Xhale, Seattle Genetics, Antares, BI Gen Holdings, Inc., Corcept Therapeutics Pharmaceuticals Company, and EMA Wellness. Scientific Advisory Boards: ANeuroTech (division of Anima BV), Brain and Behavior Research Foundation (BBRF), Anxiety and Depression Association of America (ADAA), Skyland Trail, Signant Health, Laureate Institute for Brain Research (LIBR), Inc., Magnolia CNS, and Heading Health. Board of Directors: Gratitude America, ADAA, and Xhale Smart, Inc. Patents: method and devices for transdermal delivery of lithium (US 6,375,990B1). Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2). Speakers Bureau: none. K.J.R. provides fee-for-service consultation for Biogen, Alkermes, and Resilience Therapeutics. He also holds patents for a number of targets related to improving extinction of fear; however, he has received no equity or income within the past 3 years related to these. He receives or has received research funding from NIMH, HHMI, NARSAD, and the Burroughs Wellcome Foundation. B.O.R has funding from Wounded Warrior Project, Department of Defense, National Institute of Mental Health, and McCormick Foundation. B.O.R. receives royalties from Oxford University Press, Guilford, APPI, and Emory University, and has served on recent advisory boards for Aptinyx, Sandoz, and Nobilis. N.P.D. has held a part-time paid position at Cohen Veteran Biosciences. N.P.D. has been a consultant for Sunovion Pharmaceuticals and is on the scientific advisory board for Sentio Solutions, Inc. All remaining authors declare no competing interests.